23 completed, 22 recruiting, 14 unknown, 9 active not recruiting. 31 Phase 2, 13 Not applicable, 11 Phase 1, 10 Phase 3, 2 Early Phase 1.
Follow Esophageal Carcinoma: new trials by email Literature Review of Esophageal Carcinoma trials Research Report on Esophageal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Neoadjuvant Therapy for Esophageal Cancer Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy | Not applicable | Enrolling by invitation | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 43 | 2028-03-01 | 2025-05-25 |
| Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) Paclitaxel Q2W, Paclitaxcel Q3W - Esophageal Carcinoma, Gastric Cancer (Diagnosis) | Phase 2 | Recruiting | University of California, Irvine | 55 | 2026-08-04 | 2026-08-31 |
| The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma | Recruiting | yi shen | 4 | 2026-05-15 | 2026-08-06 | |
| Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma Chemotherapy, Targeted Systemic Therapy, Immunotherapy - Esophageal Cancer, Gastric (Stomach) Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 290 | 2026-04-29 | 2026-09-10 |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays PAGODA algorithm, Oxaliplatin, Folinic Acid - Ampulla of Vater Carcinoma, Appendix Carcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 420 | 2026-02-13 | 2026-10-02 |
| Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection Indocyanine Green (IC-Green), Fluorescence guided identification using indocyanine green - Esophageal Carcinoma, Gastric Carcinoma | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 10 | 2025-09-01 | 2025-08-07 |
| Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study Proton radiotherapy, Immune Checkpoint Inhibitors - Esophageal Carcinoma | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 23 | 2025-08-01 | 2025-06-24 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal) Exercise and Nutrition, Usual Care Group - Esophageal Cancer, Esophageal Carcinoma | Not applicable | Recruiting | University of Pittsburgh | 20 | 2025-07-16 | 2026-05-26 |
| The Vanguard Study: Testing a New Way to Screen for Cancer Biospecimen Collection, Device Usage, Electronic Health Record Review - Bladder Carcinoma, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 24000 | 2025-06-18 | 2026-10-06 |
| CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC PD-1 inhibitor, Unlimited radiotherapy, TP regimen - Esophageal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Fudan University | 452 | 2025-02-01 | 2026-04-17 |
| PET-imaging of Two Vartumabs in Patients With Solid Tumors 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan - Solid Tumor, Colon Carcinoma | Early Phase 1 | Recruiting | Var2 Pharmaceuticals | 32 | 2024-12-10 | 2025-12-29 |
| Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer Feeding jejunostomy placement, Feeding jejunostomy placement at esophagectomy - Esophageal Cancer, Esophageal Carcinoma | Active not recruiting | Stefan Gutknecht | 60 | 2024-11-30 | 2026-04-23 | |
| Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) Cadonilimab ;Anlotinib - Esophageal Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 51 | 2024-11-01 | 2024-11-08 |
| TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT - Esophageal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Fudan University | 432 | 2024-11-01 | 2026-01-07 |
| Defining Musical Toxicity and Its Effect on Patient Well-being Non-Interventional Study - Breast Carcinoma, Esophageal Carcinoma | Withdrawn | Mayo Clinic | 2024-08-15 | 2025-06-04 | ||
| Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer Amiodarone Hydrochloride, Saline - Atrial Fibrillation, Esophageal Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 90 | 2024-06-21 | 2026-05-22 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
| Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age Serplulimab - Esophageal Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 50 | 2023-12-01 | 2024-04-09 |
Showing 20 of 77. Sign in to see all of them.
Esophageal Neoplasms (77) · Lung Neoplasms (14) · Stomach Neoplasms (14) · Breast Neoplasms (10) · Pancreatic Neoplasms (10) · Carcinoma, Hepatocellular (7) · Colonic Neoplasms (7) · Melanoma (7) · Ovarian Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Uterine Cervical Neoplasms (6) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Endometrial Neoplasms (5) · Prostatic Neoplasms (5)
Digestive System Diseases (77) · Digestive System Neoplasms (77) · Esophageal Diseases (77) · Gastrointestinal Diseases (77) · Neoplasms by Site (77) · Neoplasms (75) · Head and Neck Neoplasms (74) · Gastrointestinal Neoplasms (73) · Lung Diseases (21) · Respiratory Tract Diseases (21) · Respiratory Tract Neoplasms (21) · Thoracic Neoplasms (21) · Neoplasms by Histologic Type (19) · Neoplasms, Glandular and Epithelial (16) · Urogenital Diseases (15)
Paclitaxel (6) · Cisplatin (5) · Magnetic Resonance Spectroscopy (5) · Docetaxel (4) · Drug Therapy (4) · Esophagectomy (4) · Immune Checkpoint Inhibitors (4) · Irinotecan (4) · Carboplatin (3) · Chemoradiotherapy (3) · Fluorodeoxyglucose F18 (3) · Fluorouracil (3) · Nivolumab (3) · Radiation (3) · Specimen Handling (3)
National Cancer Institute (NCI) (6) · Hebei Medical University Fourth Hospital (4) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Merck Sharp & Dohme LLC (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Anhui Provincial Hospital (2) · Fudan University (2) · Jonsson Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Sun Yat-sen University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Zhejiang Cancer Hospital (2) · Alliance for Clinical Trials in Oncology (1) · Beijing Friendship Hospital (1)
China (32) · United States (30) · Netherlands (5) · Spain (4) · Germany (3) · Puerto Rico (3) · Guam (2) · France (1) · Italy (1) · Norway (1) · Slovenia (1) · Switzerland (1)
Kathrin Milbury (2) · Wenbin Shen, PhD (2) · Alexander Shoushtari (1) · Bentong Yu, Master (1) · Bhaskar Banerjee (1) · Cihan Gani, MD, PD (1) · David Ilson, MD (1) · Dean A. Shumway, M.D. (1) · Dong Qian, M.D. (1) · Gabriel A. Brooks, MD, MPH (1) · Gooitzen van Dam, MD, PhD (1) · H. WM van Laarhoven, MD, PhD, PhD (1) · Hanneke van Laarhoven, MD, PhD, PhD (1)
PMID 30308612, PMID 18498797, PMID 22668811, PMID 23199187, PMID 24078662, PMID 24888266, PMID 26576807, PMID 26586415, PMID 26980473, PMID 28187044, PMID 29128908, PMID 30570649, PMID 31127335, PMID 31226960, PMID 31748296, PMID 31809243, PMID 32416073, PMID 32463741, PMID 33026938, PMID 33048619, PMID 33198942, PMID 34036820, PMID 34171870, PMID 34550079, PMID 34730989, PMID 34973513, PMID 35133871, PMID 35138919, PMID 35852104, PMID 36351402, PMID 36512649, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38274807, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41101974, PMID 41764126, PMID 41932350, PMID 42571808
2015 (2), P30CA015704 (2), N01CM00100 (1), N01CN35158 (1), P30CA015083 (1), P30CA023074 (1), P30CA047904 (1), P50CA095060 (1), R37CA231522 (1), U01CA062490 (1), U01CA062502 (1), U01CA062505 (1), U01CA069856 (1), U01CA070095 (1), U01CA099168 (1)